CLSLPesticides & Agrochemicals
Crop Life Science Ltd — Profit & Loss Statement
₹41.00
-6.82%
Crop Life Science Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.01 Cr | — |
| Tax Rate For Calcs | 0.28 | 0.26 | 0.27 | 0.25 | — |
| Normalized EBITDA | 17.38 Cr | 15.92 Cr | 12.37 Cr | 7.93 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 5.60 Cr | 6.02 Cr | 4.07 Cr | 2.81 Cr | — |
| Reconciled Depreciation | 4.83 Cr | 4.42 Cr | 3.71 Cr | 2.25 Cr | — |
| Reconciled Cost Of Revenue | 141.70 Cr | 146.26 Cr | 93.30 Cr | 59.55 Cr | — |
| EBITDA | 17.38 Cr | 15.92 Cr | 12.37 Cr | 7.97 Cr | — |
| EBIT | 12.55 Cr | 11.50 Cr | 8.67 Cr | 5.72 Cr | — |
| Net Interest Income | -4.75 Cr | -3.39 Cr | -2.74 Cr | -2.06 Cr | — |
| Interest Expense | 4.75 Cr | 3.39 Cr | 3.07 Cr | 1.95 Cr | — |
| Normalized Income | 5.60 Cr | 6.02 Cr | 4.07 Cr | 2.78 Cr | — |
| Net Income From Continuing And Discontinued Operation | 5.60 Cr | 6.02 Cr | 4.07 Cr | 2.81 Cr | — |
| Total Expenses | 188.95 Cr | 189.22 Cr | 122.87 Cr | 96.49 Cr | — |
| Diluted NI Availto Com Stockholders | 5.60 Cr | 6.02 Cr | 4.07 Cr | 2.81 Cr | — |
| Net Income Common Stockholders | 5.60 Cr | 6.02 Cr | 4.07 Cr | 2.81 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 5.60 Cr | 6.02 Cr | 4.07 Cr | 2.81 Cr | — |
| Net Income Including Noncontrolling Interests | 5.60 Cr | 6.02 Cr | 4.07 Cr | 2.81 Cr | — |
| Net Income Continuous Operations | 5.60 Cr | 6.02 Cr | 4.07 Cr | 2.81 Cr | — |
| Tax Provision | 2.19 Cr | 2.09 Cr | 1.53 Cr | 0.95 Cr | — |
| Pretax Income | 7.80 Cr | 8.11 Cr | 5.60 Cr | 3.77 Cr | — |
| Other Non Operating Income Expenses | 0.95 Cr | 2.11 Cr | 0.02 Cr | 0.27 Cr | — |
| Net Non Operating Interest Income Expense | -4.75 Cr | -3.39 Cr | -2.74 Cr | -2.06 Cr | — |
| Interest Expense Non Operating | 4.75 Cr | 3.39 Cr | 3.07 Cr | 1.95 Cr | — |
| Operating Income | 11.60 Cr | 9.39 Cr | 8.34 Cr | 5.46 Cr | — |
| Operating Expense | 47.26 Cr | 42.96 Cr | 29.57 Cr | 36.94 Cr | — |
| Other Operating Expenses | 29.64 Cr | 28.47 Cr | 9.58 Cr | 17.02 Cr | — |
| Depreciation And Amortization In Income Statement | 4.83 Cr | 3.23 Cr | 3.71 Cr | 2.25 Cr | — |
| Depreciation Income Statement | 4.83 Cr | 3.23 Cr | 3.60 Cr | 2.13 Cr | — |
| Gross Profit | 58.86 Cr | 52.35 Cr | 37.92 Cr | 42.40 Cr | — |
| Cost Of Revenue | 141.70 Cr | 146.26 Cr | 93.30 Cr | 59.55 Cr | — |
| Total Revenue | 200.55 Cr | 198.61 Cr | 131.22 Cr | 101.95 Cr | — |
| Operating Revenue | 200.55 Cr | 198.61 Cr | 131.22 Cr | 101.95 Cr | — |
| Total Unusual Items | — | 0.53 Cr | 0.00 | 0.04 Cr | -0.23 Cr |
| Total Unusual Items Excluding Goodwill | — | 0.53 Cr | 0.00 | 0.04 Cr | -0.23 Cr |
| Interest Income | — | 1.33 Cr | 0.53 Cr | 0.01 Cr | 95000.00 |
| Rent Expense Supplemental | — | 0.15 Cr | 0.29 Cr | 1.32 Cr | 0.30 Cr |
| Diluted Average Shares | — | 1.71 Cr | 1.71 Cr | 1.71 Cr | 1.71 Cr |
| Basic Average Shares | — | 1.71 Cr | 1.71 Cr | 1.71 Cr | 1.71 Cr |
| Diluted EPS | — | 3.51 | 2.38 | 1.64 | 2.16 |
| Basic EPS | — | 3.51 | 2.38 | 1.64 | 2.16 |
| Special Income Charges | — | 0.53 Cr | 0.00 | 0.04 Cr | -0.23 Cr |
| Other Special Charges | — | -0.53 Cr | — | -0.04 Cr | -0.06 Cr |
| Total Other Finance Cost | — | 0.49 Cr | 0.20 Cr | 0.12 Cr | 0.10 Cr |
| Interest Income Non Operating | — | 1.33 Cr | 0.53 Cr | 0.01 Cr | 95000.00 |
| Amortization | — | 0.10 Cr | 0.11 Cr | 0.12 Cr | 0.12 Cr |
| Selling General And Administration | — | 5.76 Cr | 2.63 Cr | 3.74 Cr | 5.43 Cr |
| Selling And Marketing Expense | — | 2.99 Cr | 1.27 Cr | 1.80 Cr | 2.94 Cr |
| General And Administrative Expense | — | 2.77 Cr | 1.36 Cr | 1.94 Cr | 2.48 Cr |
| Rent And Landing Fees | — | 0.15 Cr | 0.29 Cr | 1.32 Cr | 0.30 Cr |
| Write Off | — | — | — | 0.00 | 0.29 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Crop Life Science Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.